✦ LIBER ✦

A phase I study of a new 5HT3-receptor antagonist, BRL43694A, an agent for the prevention of chemotherapy-induced nausea and vomiting

✍ Scribed by Geoffrey Falkson; Adriaan J. Zyl

Publisher: Springer
Year: 1989
Tongue: English
Weight: 370 KB
Volume: 24
Category: Article
ISSN: 0344-5704
DOI: 10.1007/bf00300242

No coin nor oath required. For personal study only.

✦ Synopsis

In a phase I study of BRL43694A, a 5HT3-receptor antagonist, a single dose of 40 micrograms/kg was given to 24 patients. All patients received cytostatic treatment expected to cause nausea and vomiting. During the first 24 h, 12 patients were completely protected from nausea and vomiting, 4 experienced nausea and 8 had moderate vomiting; mild headache occurred in 10 patients. No cardiovascular (including ECG) changes took place. Apart from headache, no neurological side effects occurred.

📜 SIMILAR VOLUMES

High versus low dose granisetron, a sele

High versus low dose granisetron, a selective 5HT3antagonist, for the prevention of chemotherapy-induced nausea and vomiting

✍ H. C. Falkson; C. I. Falkson; G. Falkson 📂 Article 📅 1990 🏛 Springer US 🌐 English ⚖ 173 KB

Fifty six patients, with histologically confirmed cancer, who received highly emetogenic chemotherapy, were entered on a randomized double blind, low versus high dose, study of granisetron, a 5HT3 receptor antagonist. A single dose of intravenous granisetron protected the majority of patients from n

Improved prevention of moderately emetog

Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist : Results of a Phase III, single-dose trial versus dolasetron

✍ Peter Eisenberg; Jazmin Figueroa-Vadillo; Rosalio Zamora; Veena Charu; Julio Haj 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 174 KB

## Background: Palonosetron, a highly selective and potent 5-ht(3) receptor antagonist with a strong binding affinity and a long plasma elimination half-life (approximately 40 hours), has shown efficacy in phase ii trials in preventing chemotherapy-induced nausea and vomiting (cinv) resulting from

GR38032F, a 5HT3receptor antagonist, in

GR38032F, a 5HT3receptor antagonist, in the prophylaxis of acute cisplatin-induced nausea and vomiting

✍ Michel Marty; Jean P. Droz; Pierre Pouillart; Bernard Paule; Nils Brion; Jacques 📂 Article 📅 1989 🏛 Springer 🌐 English ⚖ 330 KB

A total of 28 patients receiving cancer chemotherapy with cisplatin-containing regimens (70-120 mg/ m 2) participated in an evaluation of the efficacy and safety of GR38032F for the prevention of acute nausea and vomiting. GR38032F, a 5HT3 receptor antagonist, was given 30 min prior to cisplatin as

A randomized, multicenter study comparin

A randomized, multicenter study comparing the efficacy and tolerability of tropisetron, a new 5-HT3 receptor antagonist, with a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis

✍ Bengt G. Sorbe; Thomas Högberg; Bengt Glimelius; Margareta Schmidt; Lars Wernste 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 900 KB

Phase 2 trial results with the novel neu

Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy

✍ Wichit Arpornwirat; Istvan Albert; Vincent L. Hansen; Jeremey Levin; Rajesh R. B 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 172 KB 👁 1 views

Addition of the neurokinin 1 receptor an

Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting : Results from a randomized, double-blind, placebo-controlled trial in Latin America

✍ Sergio Poli-Bigelli; Jose Rodrigues-Pereira; Alexandra D. Carides; Guoguang Juli 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB 👁 1 views